Research on the Contrast about National Reimbursement Drug List between 2009 and 2017
- VernacularTitle:2017版和2009版国家医保药品目录对比研究
- Author:
Wei XU
1
;
Li MA
;
Nan GAO
Author Information
- Keywords: reimbursement drug; drug list; contrast
- From: Chinese Health Economics 2018;37(1):44-47
- CountryChina
- Language:Chinese
- Abstract: Objective:To explore the adjustment direction of new National Reimbursement Drug List 2017(NDRL) and provide guidance about supplement of Reimbursement Drug List for each province.Methods:Comparing the differences about NDRL between 2009 and 2017 by EXCEL and SPSS 18.0.Results:More drugs and negotiated drugs were added into the new NDRL.The classification method of western drugs had been changed.The amount of supplementary drugs was more than eliminated drugs.The main dosage of supplementary drugs form were granules and oral liquid.The growth proportion of Class-A and Class-B were similar.The government had imposed restrictions on drug indication and canceled limit to reimbursement of outpatient service.Conclusion:The new NDRL supported with the hand the traditional Chinese medicine and pays more attention to expensive drugs and pediatric drugs.It also subdivided the drug classification and make catalog management more strictly.
